Lonza to invest $15.18m for ADC manufacturing capacity expansion
Lonza is planning to expand antibody drug conjugate (ADC) manufacturing capacity in Visp, Switzerland, with an investment of CHF14m ($15.18m).
The ADC facility expansion is expected to double the present large-scale manufacturing capacity in Visp without interrupting the current operations.
Lonza chemical manufacturing business unit head Stefan Stoffel said the investment is required to continue to support the growing product demands from the customers.
"Lonza Visp will continue to offer a fully integrated end-to-end development and manufacturing solution for ADCs, including the cytotoxic small molecules used in these products and all associated analytics," Stoffel added.
"In addition, Lonza can support protein development and manufacturing via our global biologics development and manufacturing sites."
The Visp facility expansion that has the potential to create new job opportunities is expected to be completed in the second quarter of 2014.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $0